Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Tumori
|
January 6, 2022
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease
Andrea Spagnoletti, Marco Platania, Marta Brambilla, et al.
British Journal of Haematology
|
September 9, 2004
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults
Massimo Di Nicola, Carmelo Carlo-Stella, Jacopo Mariotti, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
|
November 23, 2007
Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma
Nadia Zaffaroni, Aurora Costa, Marzia Pennati, et al.
Tumori
|
March 21, 2023
Breast implant associated anaplastic large cell lymphoma: Evidence for an efficient diagnostic workup
Laura Vittoria, Laura Sala, Valeria Summo, et al.
Blood
|
September 24, 2008
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Massimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, et al.
Leukemia Research
|
May 19, 2009
Radioimmunotherapy and secondary leukemia: a case report
Michele Magni, Massimo Di Nicola, Adele Testi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 10, 2010
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
Federica Perrone, Genny Jocollè, Marzia Pennati, et al.
Oncotarget
|
October 6, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
Fabio Bozzi, Silvia Brich, Gian Paolo Dagrada, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
Giovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Haematologica
|
October 15, 2020
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Francesco Maura, Anna Dodero, Cristiana Carniti, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Tumori
|
January 6, 2022
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease
Andrea Spagnoletti, Marco Platania, Marta Brambilla, et al.
British Journal of Haematology
|
September 9, 2004
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults
Massimo Di Nicola, Carmelo Carlo-Stella, Jacopo Mariotti, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
|
November 23, 2007
Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma
Nadia Zaffaroni, Aurora Costa, Marzia Pennati, et al.
Tumori
|
March 21, 2023
Breast implant associated anaplastic large cell lymphoma: Evidence for an efficient diagnostic workup
Laura Vittoria, Laura Sala, Valeria Summo, et al.
Blood
|
September 24, 2008
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Massimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, et al.
Leukemia Research
|
May 19, 2009
Radioimmunotherapy and secondary leukemia: a case report
Michele Magni, Massimo Di Nicola, Adele Testi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 10, 2010
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
Federica Perrone, Genny Jocollè, Marzia Pennati, et al.
Oncotarget
|
October 6, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
Fabio Bozzi, Silvia Brich, Gian Paolo Dagrada, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
Giovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Haematologica
|
October 15, 2020
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Francesco Maura, Anna Dodero, Cristiana Carniti, et al.
Page
of 3